REPLICor to Present at 20th International Conference on Antiviral Research
Laval, Quebec – April 23, 2007 -- REPLICor announced today that Dr. Andrew Vaillant, Chief Scientific Officer, will be presenting at the 20th International Conference on Antiviral Research (Palm Springs, CA, April 29 – May 3, 2007). He will make a presentation titled “A Novel Class of Amphipathic DNA Polymers Inhibits Hepatitis C Virus Infection by Blocking Viral Entry.
About REPLICor:
REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors targeting hepatitis C (HCV) and influenza. REPLICor has demonstrated that REP 9C have potent in vivo activity against HCV, influenza and other enveloped viruses. The drug is active by oral administration and well tolerated in multiple animal studies. REP 9C can readily be synthesized in large quantities in cGMP facilities. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its products.
For more information:
Andrew Vaillant PhD, CSO
REPLICor Inc.
450-688-6068